Interferon: Benefit beyond hepatitis therapy?

American Journal of Gastroenterology

Volumn 96, Issue 12, 2001, Pages 3435-3436

  Mallat, Damien B ^a   El Serag, Hashem B ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT;

CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FOLLOW UP; GENOTYPE; HEPATITIS C; HUMAN; INCIDENCE; MALE; NOTE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0035659602     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(01)03933-8     Document Type: Note

References (10)

1. Global epidemiology of hepatocellular carcinoma
2. Randomized trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis
3. Long-term follow-up study of sustained biochemical responders with interferon therapy
4. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: An evidence-based approach
5. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: A meta-analysis
6. Preliminary results of interferon-alpha therapy on woodchuck hepatitis virus-induced hepatocaminogenesis: Possible benefit in female transgenic mice
7. Tumor-suppressor effect of interferon regulatory factor-1 in human hepatocellular carcinoma
8. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor - A prospective randomized study of hepatitis C virus-related liver cancer
9. Risk factors for recurrence after resection of hepatitis C virus-related hepatocellular carcinoma
10. Long-term survival following treatment of hepatocellular carcinoma in Singapore: Evaluation of Wellferon in the prophylaxis of high-risk pre-cancerous conditions